MAN05 Ultra-long Acting Bronchodilator Therapy in Smoking Asthmatics

  • Research type

    Research Study

  • Full title

    Effects of ultra-long acting bronchodilator therapy assessed by impulse oscillometry in smoking asthmatics taking inhaled corticosteroids

  • IRAS ID

    172226

  • Contact name

    Sunny Jabbal

  • Contact email

    s.jabbal@dundee.ac.uk

  • Sponsor organisation

    University of Dundee

  • Eudract number

    2014-005317-23

  • Duration of Study in the UK

    2 years, 0 months, 1 days

  • Research summary

    Cigarette smoking in asthma is associated with poorer asthma control and a higher frequency of asthma attacks. Despite this, smoking cessation rates are very low due to the highly addictive nature of tobacco smoking. Asthma in smokers is particularly challenging to manage because it is resistant to the beneficial effects of inhaled corticosteroids, the main treatment for asthma.
    Unfortunately, there is no guideline consensus regarding how to best manage asthmatics who smoke. Research studies in asthma tend to exclude smokers because of concerns about recruiting patients with chronic obstructive pulmonary disease (COPD). Hence, there is an unmet need for research studies in asthmatics who are unable to stop smoking.
    In view of the above, we propose to assess the effects of two different types of bronchodilators (inhalers which help open up the airways), in asthmatics who continue to smoke. The first inhaler is olodaterol which is a new long-acting bronchodilator. The second inhaler is tiotropium. We wish to compare the inhalers using a sensitive breathing test called impulse oscillometry.

  • REC name

    East of Scotland Research Ethics Service REC 2

  • REC reference

    15/ES/0032

  • Date of REC Opinion

    24 Jul 2015

  • REC opinion

    Further Information Favourable Opinion